论文信息 - Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer. - 字舞流文

Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer.

S. Peacock | C. Lohrisch | S. Chia | C. Speers | L. Hedden | S. O'Reilly | L. Kovacic | Suzanne Taylor | S. Taylor